This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gurnell, E. M. Articles by Chatterjee, V. K. K. Search for Related Content PubMed PubMed Citation Articles by Gurnell, E. M. Articles by Chatterjee, V. K. K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Addison's Disease Hormone Replacement Therapy Related Collections Adrenal and Hypertension

Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial

Department of Public Health and Primary Care, Centre for Applied Medical Statistics (E.M.P.), Departments of Medicine (E.M.G., S.E.C., J.E.C., V.K.K.C.), Psychiatry (F.A.H.), and Anatomy and Cambridge Centre for Brain Repair (J.H.), University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom; and Department of Endocrinology (P.J.H., C.L.C.), Christchurch Hospital, Christchurch 8140, New Zealand

Address all correspondence and requests for reprints to: Professor Krishna Chatterjee, Department of Medicine, Level 5, Box 157, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom. E-mail: kkc1{at}mole.bio.cam.ac.uk.

Context: Dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) are the major circulating adrenal steroids and substrates for peripheral sex hormone biosynthesis. In Addison’s disease, glucocorticoid and mineralocorticoid deficiencies require lifelong replacement, but the associated near-total failure of DHEA synthesis is not typically corrected.

Objective and Design: In a double-blind trial, we randomized 106 subjects (44 males, 62 females) with Addison’s disease to receive either 50 mg daily of micronized DHEA or placebo orally for 12 months to evaluate its longer-term effects on bone mineral density, body composition, and cognitive function together with well-being and fatigue.

Results: Circulating DHEAS and androstenedione rose significantly in both sexes, with testosterone increasing to low normal levels only in females. DHEA reversed ongoing loss of bone mineral density at the femoral neck (P < 0.05) but not at other sites; DHEA enhanced total body (P = 0.02) and truncal (P = 0.017) lean mass significantly with no change in fat mass. At baseline, subscales of psychological well-being in questionnaires (Short Form-36, General Health Questionnaire-30), were significantly worse in Addison’s patients vs. control populations (P < 0.001), and one subscale of SF-36 improved significantly (P = 0.004) after DHEA treatment. There was no significant benefit of DHEA treatment on fatigue or cognitive or sexual function. Supraphysiological DHEAS levels were achieved in some older females who experienced mild androgenic side effects.

Conclusion: Although further long-term studies of DHEA therapy, with dosage adjustment, are desirable, our results support some beneficial effects of prolonged DHEA treatment in Addison’s disease.

This article has been cited by other articles:

				M. Maggio, G. P. Ceda, S. Basaria, G. Valenti, and L. Ferrucci Dehydroepiandrosterone Sulfate Has Not Been Substantiated as an Anabolic Hormone--Reply Arch Intern Med, July 14, 2008; 168(13): 1470 - 1470. [Full Text] [PDF]